Skip to content
    Andera Partners logo

    Andera Partners

    Paris, FranceFounded 2001
    www.anderapartners.com/enLinkedIn
    Biotech & Life SciencesEnterprise SoftwareHealthcare

    Andera Partners is a private equity firm that focuses on supporting companies and their managers in achieving strong, sustainable growth across several key areas. Their investment strategies include life sciences, green innovative infrastructures, and European SMEs and mid-caps through growth, buyout, and sponsorless mezzanine financing. The firm emphasizes innovation and sustainability as core to its approach, acting as a sparring partner for entrepreneurs to drive organic and external growth, international development, and corporate governance.

    76% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (44% of deals). Average disclosed round size is $97.9M (across 24 rounds with reported amounts).

    Find people at Andera Partners on Goldilocks AI

    Portfolio

    25

    Fund Size

    $5.1B

    Top Stage

    Series A

    Last 12 Mo

    7

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    25 investments
    CompanyRoundAmountDate
    Exciva logoExcivaSeries B$59MJan 2026
    Alveus Therapeutics Inc logoAlveus Therapeutics IncSeries A$160MJan 2026
    Spiro Medical, Inc. logoSpiro Medical, Inc.Series A$67MJan 2026
    TargED Biopharmaceuticals logoTargED BiopharmaceuticalsSeries A$21.5MDec 2025
    Artios Pharma Limited logoArtios Pharma LimitedSeries D$115MNov 2025
    Adcytherix logoAdcytherixSeries A$105MOct 2025
    Tubulis logoTubulisSeries C$308MOct 2025
    EG 427 logoEG 427Series B$27MFeb 2025
    EExciva GmbHSeries B$59MJan 2025
    Bioptimus logoBioptimusSeries A$41MJan 2025
    Evommune, Inc. logoEvommune, Inc.Series C$115MOct 2024
    IInventivaUnknown$410MOct 2024
    SciRhom GmbH logoSciRhom GmbHSeries A$70MJul 2024
    DDualyxSeries A$44MMay 2023
    Evommune, Inc. logoEvommune, Inc.Series B$50MApr 2023
    BBioVentrix, Inc.Series A$48.5MApr 2023
    Mineralys Therapeutics, Inc. logoMineralys Therapeutics, Inc.Series B$118MJun 2022
    TargED Biopharmaceuticals logoTargED BiopharmaceuticalsSeries A$39MFeb 2022
    Evommune, Inc. logoEvommune, Inc.Series A$83MSep 2021
    Artios Pharma Limited logoArtios Pharma LimitedSeries C$153MJul 2021
    AAgomAb TherapeuticsSeries B$74MMar 2021
    TT-knife GmbHSeries A$66MAug 2020
    HHighLife SASSeries B$32MJan 2019
    Artios Pharma Limited logoArtios Pharma LimitedSeries B$84MAug 2018
    Arvelle Therapeutics logoArvelle TherapeuticsUnknown——

    Top Co-Investors

    EQT Life Sciences6 shared
    RA Capital Management5 shared
    Sofinnova Partners4 shared
    Omega Funds4 shared
    LSP4 shared
    Bpifrance3 shared
    Kurma Partners3 shared
    Pivotal bioVenture Partners3 shared
    Fountain Healthcare3 shared
    Deep Track Capital3 shared
    Invus3 shared
    HTGF3 shared
    Sectoral Asset Management3 shared
    RTW Investments3 shared
    M Ventures3 shared
    Novartis Venture Fund3 shared
    Pfizer Ventures3 shared
    SV Health Investors3 shared
    INKEF Capital2 shared
    Gimv2 shared

    Last updated: 12 April 2026